-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 18th National Conference on Red Blood Cell Disease (Anemia), sponsored by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, undertaken by the Henan Medical Association, and co-organized by the First Affiliated Hospital of Zhengzhou University and the Second Hospital of Lanzhou University, was grandly opened
Opening Ceremony Speech Expert (Swipe left and right to see more)
Professor Shao Zonghong gave an academic report
Professor Hu Yu gave an academic report
Professor Huang Xiaojun gave an academic report
Professor An Xiuli gave an academic lecture
Professor Liu Limin gave an academic report
Bone marrow failure immune yin and yang
Under the presidency of Professor Niu Ting of West China Hospital of Sichuan University and Professor Zhang Xi of the Second Affiliated Hospital of army military medical university (Xinqiao Hospital), Professor Zhang Liansheng introduced the "yin" and "yang" of immunity in bone marrow failure diseases with the topic of "bone marrow failure immunity yin and yang"
.
The so-called "yin" is immune tolerance, and "yang" is hyperimmune
.
Professor Zhang Liansheng said that the balance of immune yin and yang is very important
in the understanding of blood diseases.
Early recognition of immune yin-yang status will help patients with precise treatment
.
In addition, in patients with MDS, different immune yin and yang states can lead to different clinical manifestations, and there is a interaction or mutual transformation of hyperimmune immune and immune tolerance, in which case immunity and molecular testing are required to combine to identify this type of patient
.
Professor Zhang Liansheng gave an academic report
CAR-T therapy after transplant recurrence
Under the auspices of Professors Ma Jun and Qiu Lin of Harbin Institute of Hematology and Oncology and Professor Song Yongping of the First Affiliated Hospital of Zhengzhou University, Professor Liu Kaiyan of Peking University People's Hospital introduced the efficacy and safety
of CAR-T cell therapy after relapsed transplantation with the title of "CAR-T treatment after relapsed transplantation of acute lymphoblastic leukemia".
Whether it is bone marrow failure disease or leukemia, hematopoietic stem cell transplantation is a very important treatment
.
Post-transplant death is mainly attributed to recurrence of the primary disease, and solving the problem of recurrence is very important
to improve the survival of patients.
Professor Liu Kaiyan concluded that compared with traditional treatments (symptomatic supportive therapy, chemotherapy-based donor leukocyte infusion and secondary transplantation, etc.
) and antibody therapy, CAR-T cell therapy is more
effective in patients with recurrent acute B-lymphocytic leukemia (B-ALL) after allo-HSCT.
In addition, secondary transplantation can enable long-term survival
in some patients.
Professor Liu Kaiyan gave an academic report
summary
At this point, the opening ceremony and the part of the conference report on the morning of the 9th ended
.
The smooth convening of this meeting has brought new thinking
to the diagnosis and treatment of erythrocyte disease.
The wonderful and in-depth exchanges and discussions at the meeting benefited the colleagues a lot and laid the foundation
for the successful convening of the conference.
In the future, the majority of colleagues will jointly carry forward the spirit of the "Red Army", take "curing" more patients as their responsibility, and bravely climb the peak and continue to move forward on the road of exploration of red blood cell disease treatment!
Poke "Read the original article" to see more